{"id":425377,"date":"2025-04-01T00:00:00","date_gmt":"2025-04-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0042-2025-biopharma-schizophrenia-unmet-need-unmet-need-treatment-resistant-schizophrenia-us-eu\/"},"modified":"2026-04-18T23:11:48","modified_gmt":"2026-04-18T23:11:48","slug":"unnecg0042-2025-biopharma-schizophrenia-unmet-need-unmet-need-treatment-resistant-schizophrenia-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0042-2025-biopharma-schizophrenia-unmet-need-unmet-need-treatment-resistant-schizophrenia-us-eu\/","title":{"rendered":"Schizophrenia &#8211; Unmet Need &#8211; Unmet Need &#8211; Treatment Resistant Schizophrenia (US\/EU)"},"content":{"rendered":"<p>Most psychiatrists define <abbr data-abbreviation-entity=\"8270\" title=\"treatment-resistant schizophrenia\">TRS<\/abbr> as a lack of response to at least two treatment changes. Currently, clozapine is the only approved drug for this condition, but its use is limited due to safety concerns associated with a black box warning, poor tolerability, and the need for regular blood monitoring. Additionally, a significant proportion of <abbr title=\"treatment-resistant schizophrenia\">TRS<\/abbr> patients fail to respond adequately to clozapine, leaving them with limited treatment options. The late-stage pipeline for <abbr title=\"treatment-resistant schizophrenia\">TRS<\/abbr> is sparse. Notably, Newron Pharmaceuticals is investigating evenamide as an add-on treatment to antipsychotics for <abbr title=\"treatment-resistant schizophrenia\">TRS<\/abbr> patients. The drug has shown positive efficacy and safety in Phase 2. With up to 30% of drug-treated schizophrenia patients being treatment-resistant, this patient segment represents a substantial commercial opportunity for safe and effective treatments.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which clinical\/nonclinical attributes for a therapy will influence psychiatrists\u2019 treatment decisions for <abbr title=\"treatment-resistant schizophrenia\">TRS<\/abbr> patients?<\/li>\n<li>How do psychiatrists rate the performance of key current therapies on treatment drivers and goals for <abbr title=\"treatment-resistant schizophrenia\">TRS<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need in <abbr title=\"treatment-resistant schizophrenia\">TRS<\/abbr>?<\/li>\n<li>What are the key opportunities for drug development in <abbr title=\"treatment-resistant schizophrenia\">TRS<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p>Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<p><strong>Markets covered: <\/strong>United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 32 European psychiatrists fielded in February 2025<\/p>\n<p><strong>Key companies: <\/strong>Otsuka Pharmaceutical, Lundbeck, Eli Lilly, Johnson &#038; Johnson Innovative Medicine, AbbVie, Recordati<\/p>\n<p><strong>Key drugs: <\/strong>Clozapine,<strong> <\/strong>aripiprazole, risperidone, paliperidone palmitate, olanzapine, brexpiprazole, cariprazine<\/p>\n","protected":false},"template":"","class_list":["post-425377","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psychiatry","biopharma-therapy-areas-schizophrenia","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/425377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/425377\/revisions"}],"predecessor-version":[{"id":575804,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/425377\/revisions\/575804"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=425377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}